Immunex Files Supplemental NDA for NOVANTRONE

Company seeks priority review of NOVATRONE in secondary progressive Multiple Sclerosis

SEATTLE - Immunex Corporation (NASDAQ:IMNX) announced today that it has filed a supplemental NDA with the U.S. Food and Drug Administration (FDA) for expanded labeling for NOVANTRONE® (mitoxantrone for injection concentrate) for the treatment of patients with secondary progressive Multiple Sclerosis (MS).

"There are 120,000 patients with secondary progressive MS for whom there are still no approved treatment options," said Peggy V. Phillips, senior vice president, pharmaceutical development for Immunex. "Patients with this form of the disease experience a steady worsening of their neurological function which can result in loss of control over movement of limbs and impaired vision and speech. We are pleased to be filing this and we have asked the FDA for priority review."

The results of the pivotal NOVANTRONE Phase III data submitted to the FDA today showed that NOVANTRONE had a statistically significant impact on relapse rate and disability progression in patients with secondary progressive MS. These clinical data were corroborated by positive magnetic resonance imaging (MRI) data.

This multicenter, placebo-controlled, randomized, observer-blind study of 194 patients compared two doses of NOVANTRONE -- 12 mg/m2 and 5 mg/m2 - with placebo. Each treatment was administered by short, IV infusion once every three months for two years. These results were reported at the September 1998 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

Additional third-year follow-up data were presented in April of this year at the Annual Meeting of the American Academy of Neurology (AAN). These results showed that one year after treatment was stopped, patients who had been treated with NOVANTRONE experienced a sustained reduction in their number of attacks, and delay in their disab

Contact: Lisa Crisera
Immunex Corporation

Page: 1 2 3

Related medicine news :

1. Immunex Advances CD40 Ligand To Phase II Clinical Trial In People With Metastatic Kidney Cancer
2. Immunexs TRAIL Molecule Shows Potential As Anti-Tumor Agent
3. Mad hatters, seafood jubilees, & Pfiesteria Files
4. NOVANTRONE application for multiple sclerosis granted priority review by FDA

Post Your Comments:

(Date:2/13/2019)... , ... February 13, 2019 , ... ... 2019, at the company’s annual member conference, Elevate 2019 at the Gaylord Rockies ... staff and members to explore potential partnerships driving improved quality of patient care, ...
(Date:2/13/2019)... ... February 13, 2019 , ... American Vision Partners, ... the nation, announced a new addition to their growing list of ophthalmology brands: ... within a multi-specialty ophthalmology practice. , Dr. Zachary Berbos, MD, FACS, ...
(Date:2/13/2019)... ... February 13, 2019 , ... Asana Recovery is accepting ... students who choose to pursue a medical-related course of study in California, the $1,000 ... substance abuse disorder and mental health treatment, and how it has led them to ...
(Date:2/12/2019)... ... February 12, 2019 , ... Medical Device Risk ... Ombu Enterprises**, Feb. 19-20, 2019, Atlanta, GA , https://www.fdanews.com/mdriskmanagement , One ... of Change on Jan. 22 , Risk management is just plain hard, complicated, ...
(Date:2/11/2019)... ... February 11, 2019 , ... Caring Health Systems ... integrated suite could more effectively manage its complex environment of 1,100+ employees across ... client, Caring Health chose SmartLinx to automate its changing staffing needs, such as ...
Breaking Medicine News(10 mins):
(Date:2/13/2019)... ... February 13, 2019 , ... The Medicus Firm (TMF) ... Physician Recruiters (ASPR). “The Medicus Firm has been a vocal and enthusiastic supporter ... stewardship and support of educational programs are part of our DNA and becoming a ...
(Date:2/13/2019)... , ... February 13, 2019 , ... Co-founded in a ... aims to give women an empowering place to not only exercise, but to nurture ... CEO Devan is a former professional baseball player with the San Francisco Giants and ...
(Date:2/13/2019)... & ORLANDO, Fla. (PRWEB) , ... February 13, ... ... platform for voice and chatbot applications in healthcare, today announced through its collaboration ... two additional platforms: Google Assistant and voice-powered web chat. This takes Mayo ...
Breaking Medicine Technology:
Cached News: